SIBP-A13 / Sinopharm - LARVOL DELTA

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: Shanghai Institute Of Biological Products | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. (clinicaltrials.gov) - P1 | N=144 | Not yet recruiting | Sponsor: Shanghai Institute Of Biological Products

Metastases • New P1 trial • Oncology • Solid Tumor

The first ADC drug independently developed by China National Biotechnology Shanghai Institute of Biological Products has been approved for clinical use [Google translation] (Shanghai Institute of Biological Products) - "...SIBP-A13, the first innovative antibody conjugate drug (ADC) independently developed by China Biotechnology Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration and is intended to be used in patients with advanced malignant solid tumors. Conduct clinical trials."

New trial • Oncology • Solid Tumor